14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
ACTU vs SABA: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
SABA Wins Head-to-Head Institutional Verdict (2–2 across 6 Pillars · 4–4 Matrix Metrics)
SABA Overall Winner
6-Pillar Tally: ACTU 2 – 2 SABA (2 Tie)
Matrix Metrics: ACTU 4 – 4 SABA
As of Nov 20, 2026, Saba Capital Income & Opportunities Fund II (SABA) is the stronger overall head-to-head candidate over Actuate Therapeutics, Inc. (ACTU) in the Tradestie Institutional Equity Comparison Engine, winning 4–4 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Balance Sheet & Cash Flow, Options & Positioning). ACTU carries a Unified Composite Score of 35.1/100 (SELL) at $0.23 (N/M Forward P/E, 0.0% operating margin), whereas SABA carries 44.2/100 (HOLD) at $7.33 (N/M Forward P/E, N/A operating margin).
Technical & Structure Timing Caution: ACTU is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 28.8); meanwhile SABA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 29.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ACTU vs SABA. Trailing 12-month operating profitability (ACTU 0.0% vs SABA N/A) and valuation multiples (ACTU N/M vs SABA N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $12.9M market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
SABA Moat ProfileCyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with $251.8M market capitalization and N/A operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ ACTU vs SABA Key Questions & Quantitative Answers
As of Nov 20, 2026, Saba Capital Income & Opportunities Fund II (SABA) is the stronger overall head-to-head candidate over Actuate Therapeutics, Inc. (ACTU) in the Tradestie Institutional Equity Comparison Engine, winning 4–4 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Balance Sheet & Cash Flow, Options & Positioning). ACTU carries a Unified Composite Score of 35.1/100 (SELL) at $0.23 (N/M Forward P/E, 0.0% operating margin), whereas SABA carries 44.2/100 (HOLD) at $7.33 (N/M Forward P/E, N/A operating margin). Technical & Structure Timing Caution: ACTU is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 28.8); meanwhile SABA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 29.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
ACTU leads the Growth & Scale pillar: ACTU posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with SABA at N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin). On trailing 12-month operating scale, ACTU generates N/A in USD-normalized revenue versus N/A for SABA. In operating R&D and SG&A reinvestment, ACTU deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for SABA.
ACTU and SABA trade at balanced relative valuation multiples. ACTU trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas SABA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ACTU (-553.8% ROE) versus SABA (N/A ROE) capital efficiency.
In options market volatility and institutional positioning, ACTU carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.64β · 114% Vol realized risk). By comparison, SABA carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.37β · 13% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.